drugset / Trial / NCT01832948

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

NCT01832948

Phase 2 Unknown 30 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study is to assess the efficacy and safety of Endostar combined with mFOLFOX6 in untreated metastatic colorectal cancer patients, and to find the markers that may predict the efficacy.

Timeline

Start
2013-01
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 15 mg
Background Leucovorin Small molecule 400 mg/m2
Background Oxaliplatin Small molecule 85 mg/m2
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications